U.S. biotech giant Amgen is looking to acquire a biotech company worth about $10 billion, according to Financial Times sources.
FT sources said Amgen is targeting biotech firms that have late-stage drugs which are almost commercial-ready.
Amgen's last major acquisition was in 2013, when it purchased Onyx Pharmaceuticals and its cancer drug Kyprolis for about $10 billion.
Sources did not reveal any potential acquisition targets.
Read the FT article (registration required)
Read the LA Business Journal release